is tirzepatide a glp-1 agonist (Zepbound) – New Treatment for Obstructive Sleep Apnea and Obesity — BetterNight Retatrutide vs Tirzepatide: Which Weight-Loss

04:59 Wed, Mar 6 20245:45 PM EST News Tips Got a confidential news tip

The worldwide GLP-1 Receptor Agonist Market Size is expected to reach USD 24.2 Billion by 2032

Neuroprotection may be an additional benefit among initiators of SGLT2 inhibitors with atherosclerotic cardiovascular disease and renal insufficiency, in which the absolute rates of dementia were higher

In consideration of JMs desire for a once-weekly product and a desire to add an agent with proven cardiovascular benefit and notable weight loss, injectable semaglutide was selected and initiated

Available from: Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D et al (2024) Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial